Playlist: Peter Hofland's Portfolio
Featured
Disparities in Cancer Care Represent a Major Public Health Problem
From Peter Hofland | Part of the The OncoZine Brief series | 25:02
In this episode of The Onco’Zine Brief hosts Peter Hofland, Ph.D and Sonia Portillo interview Michael A. Caligiuri, MD, the current president of the American Association for Cancer Research | AACR.
In this episode of The Onco’Zine Brief hosts Peter Hofland, Ph.D and Sonia Portillo talk with Michael A. Caligiuri, MD, the current president of the American Association for Cancer Research | AACR.
Caligiuri is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, located in Columbus, Ohio. He is a renowned physician-scientist, known for his work in immunology that is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. Well over 1,500 cancer patients have been treated on clinical protocols that have come out of Caligiuri’s laboratory.
Caligiuri has been actively involved with the AACR since 1990, serving as a member, and more recently, chairperson of the Publications Committee and a member of the Clinical and Translational Cancer Research Committee, among other things.
During the 2017 annual meeting of the American Association for Cancer Research | AACR Hofland and Portillo sat down with Caligiuri to ask him about his passion, his drive and what he wants to accomplish during his tenure as president of the organization.
One of Caligiuri main concerns is the health disparities in cancer that represent a major public health problem in our country. By promoting the exchange of novel ideas and information between the AACR and a wide range of professionals from academia, industry, government, and the community, Caligiuri hopes to drive a movement to help eliminate the disparities and harness the potential and maximize the many opportunities for bringing research on health disparities from bench to bedside or community, and back again. As part of this effort, he will, during his tenure as president of the AACR, bring together scientists and other professionals working in a variety of disciplines to discuss the latest findings in the field and to stimulate the development of new research in cancer health disparities.
Dr. Google Calling MedAnswers: An interview with Alice Cresci
From Peter Hofland | Part of the The OncoZine Brief series | 29:10
Alice Crisci is a cancer survivor. As part of her journey Crisci founded Fertile Action, a cancer charity established to ensure fertile people touched by cancer can become mothers.
Crisci is also the founder of MedAnswers, a digital health app that connects anonymous patients, to board certified experts in various medical disciplines for personalized question and answer sessions.
Alice Crisci is a cancer survivor. As part of her journey Crisci founded Fertile Action, a cancer charity established to ensure fertile people touched by cancer can become mothers. As a cancer survivor and a single mom who faced issues of infertility, Alice dealt with the challenges of figuring out how preserve her firtility so that one day she could have a child.Her need resulted in the founding of a non-profit organization – Fertile Acton – which provides Education and Advocacy, offering empowering education to patients and physicians, and help oncologists have specific fertility conversation with patients during the treatment planning phase
Crisci founded Fertile Action a few weeks after she was diagnosed with breast cancer. At that time she was just 31-years-old.
Crisci also launched MedAnswers, a digital health app that connects anonymous patients, to board certified experts in various medical disciplines for personalized question and answer sessions.
Alcohol: A Modifiable Risk Factor for Cancer - An interview with John E. Mendelson, MD
From Peter Hofland | Part of the The OncoZine Brief series | 52:38
Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies. This risk is, however, potentially modifiable.
Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies.
This risk is, however, potentially modifiable.
But despite the avaiable evidence of a strong link between alcohol drinking and various types of cancers, including oropharyngeal and larynx cancer, esophageal cancer, hepatocellular carcinoma, breast cancer, and colon cancer, physician knowledge of alcohol use and cancer risk is very limited.
And the general public does not understand - or associate - drinking alsochol - including beer, wine and hard liquar - with an increased risk of cancer risk in their lifetimes.
But the risk is real.
The American Society of Clinical Oncology estimates that 5% to 6% of new cancers and cancer deaths worldwide are directly attributable to alcohol.
In an interview with Peter Hofland and Sonia Portillo, John E. Mendelson, MD of Ria Health, a provoder of effective alcohol treatment talks about the risk and how to avoid it.
Mendelson , co-founder of Ria Health, has a deep empathy for people suffering from the symptoms of alcohol abuse. He believes that medicines which are proven safe and effective should be used, and that patients’ outcomes must be measured objectively whenever possible. Medelson practices evidence-based medicine, and is passionate about the possibilities of contributing new knowledge to the medical community.
For more about alcohol and cancer read:
- Alcohol Linked to Cancer - Evidence Calles for Reduced Alcohol Consumption [Onco'Zine - November 8, 2017]
A Conversation with Dr. Anna Sureda, Head of the Hematology Department at the Catalan Institute of Oncology
From Peter Hofland | Part of the The OncoZine Brief series | 43:18
In this Edition of the OncoZine Brief, recorded during the 59th annual meeting of the American Society of Hematology, held December 9 to 12, 2017 in Atlanta, Georgia, we talk with Anna Sureda, MD, Ph.D, Head of the Hematology Department at the Catalan Institute of Oncology, Barcelona, Spain - to discuss some of the exciting developments in the treatment of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma. During our conversation we asked Dr Sureda about the exciting treatment options presented here in Atlanta as well as the differences in how patients are being treated in the United States vs. Spain. And we asked Dr Sureda about a particular study, the ECHELON-1, about the reason for the study, the study outcomes and what the results of this study mean for patients with advanced frontline Hodgkin lymphoma.
In this Edition of the OncoZine Brief, recorded during the 59th annual meeting of the American Society of Hematology, held December 9 to 12, 2017 in Atlanta, Georgia, we talk with Anna Sureda, MD, Ph.D, Head of the Hematology Department at the Catalan Institute of Oncology, Barcelona, Spain - to discuss some of the exciting developments in the treatment of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma.
During our conversation we asked Dr Sureda about the exciting treatment options presented here in Atlanta as well as the differences in how patients are being treated in the United States vs. Spain. And we asked Dr Sureda about a particular study, the ECHELON-1, about the reason for the study, the study outcomes and what the results of this study mean for patients with advanced frontline Hodgkin lymphoma.
A Cure Within - Understanding the Power of the Immune System in the Treatment of Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 38:03
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D and Sonia Portillo are speaking with Joshua A. Hill, MD, an Associate in Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center in Seattle Washington. Dr. Hill is also an attending physician at the Seattle Cancer Care Alliance, as well as an Assistant Professor at the University of Washington.
Hofland and Portillo talk about a new book – A Cure Within, published by Cold Spring Harbor Laboratory Press and written by veteran journalist and author Neil Canavan.
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D and Sonia Portillo are speaking with Joshua A. Hill, MD, an Associate in Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center in Seattle Washington. Dr. Hill is also an attending physician at the Seattle Cancer Care Alliance, as well as an Assistant Professor at the University of Washington.
In today's show Hofland and Portillo ask Dr. Hill about CAR T cell therapy- a technology that holds very high expectations for the future of cancer care. In a number of clinical trials in certain severe cancer types, CAR-Ts have shown remission rates up to 94%, which is very impressive considering most patients in CAR T trials have not responded to many, if not all other available treatments.
The first two CAR-T have recently been approved- and now there are over 240 CAR-T clinical trials that are ongoing. And while the CAR-T field is booming, and the technology is very exciting, there are severe side effects in clinical trials that lead us to believe the technology might not be ready, or might not be worth it’s very high price tag.
Hofland and Portillo speak with Dr. Hill about some of his research regarding the risk of infection in CAR T patients, as well as his perspective on where this technology is going in the near future.
And finally, Hofland and Portillo talk about a new book – A Cure Within, published by Cold Spring Harbor Laboratory Press and written by veteran journalist and author Neil Canavan.
Canavan's book discusses the power of the immune system and tells the story of a the tenacious few medical scientists who refused to abandon novel scientific concepts.
Based entirely on interviews with medical researchers the book tells the story of the pioneers of immuno-oncology. It’s a story of failure, resurrection and success.
But above all, it’s a story about discovery and intuition and cunning. It’s a peek into the lives and thoughts of some of the most gifted men and women – the medical scientists – who are, on a daily basis - working hard to find a Cure for Cancer.
The Development of Probody Therapeutics for the Targeting of Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 37:41
In this edition of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk Sean McCarthy, D.Phil, President and Chief Executive Officer of CytomX, a biotechnology company developing a novel 'Probody Platform' which allows them to design therapeutic drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation.
In addition to his work for CytomX, McCarthy is the author on multiple peer-reviewed scientific publications, issued patents and filed patent applications.
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody™ therapeutics. In the interview with Sean McCarty, Hofland and Portillo talk about the history of of Cytomx, the development of a new class of highly targeted drugs, basic research and the company’s collaboration with industry partners.
In this edition of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk Sean McCarthy, D.Phil, President and Chief Executive Officer of CytomX, a biotechnology company developing a novel 'Probody Platform' which allows them to design therapeutic drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation.
In addition to his work for CytomX, McCarthy is the author on multiple peer-reviewed scientific publications, issued patents and filed patent applications.
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody™ therapeutics. In the interview with Sean McCarty, Hofland and Portillo talk about the history of of Cytomx, the development of a new class of highly targeted drugs, basic research and the company’s collaboration with industry partners.
In late 2017, Bristol-Myers Squibb, one of the company's industry partners, received acceptance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for a CTLA-4-directed Probody™ therapeutic. CTLA-4, the clinically validated target of the Bristol-Myers Squibb checkpoint inhibitor ipilimumab (Yervoy®), the first target to advance into the clinic under the companies’ strategic collaboration formed in May 2014.
Hofland and Portillo also McCarty about the potential of his company's Probody Therapeutics and how this technology may ultimately change cancer treatment. They ask him where this technology fits in with other available cancer treatments, what patient populations can ultimately benefit most from Probody Therapeutics, how do these novel agents address the unmet needs patients are currently facing.
A Novel Treatment Option for Hepatocellular Carcinoma
From Peter Hofland | Part of the The OncoZine Brief series | 39:33
In this edition of the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer at Excelixis.
Following early work in model genetic systems, Exelixis established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. The company discovered and developed its lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in an effort to bring these medicines to patients globally.
In this edition of the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer at Excelixis.
Following early work in model genetic systems, Exelixis established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. The company discovered and developed its lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in an effort to bring these medicines to patients globally.
Hofland and Portillo ask Schwab about hepatocellular carcinoma or HCC, the most common, primary malignancy of the liver and the fifth most common cancer in men, worldwide, and seventh among women, with the highest incidence in Asian and developing countries. They talk about the disease, diagnoses and treatment. And they talk about Exelixis' global phase III Celestial trial with cabozantinib, a novel cancer agent which met its primary endpoint of overall survival (OS), and providing a clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular carcinoma.
In their concluding commentary Hofland and Portillo talk about the process of cancer staging.
Computational Oncology and Tumor Modeling - The Next Phase in Personalized Therapies for Cancer Patients.
From Peter Hofland | Part of the The OncoZine Brief series | 41:01
In this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Thomas Yankeelov, Ph.D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.
Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School. He holds the W.A. "Tex" Moncrief Jr., Simulation-Based Engineering and Sciences Professorship II – Computational Oncology and leads the Tumor Modeling Group in the university’s Institute for Computational Engineering and Sciences.
Yankeelov is the recipient of a distinguished $6 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT). He was The University of Texas’ first faculty member to hold positions in both the engineering and medical schools.
Yankeelov clinical research focuses on improving patient care by employing advanced imaging methods for the early identification, assessment and prediction of tumors and their response to therapy.
In this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Thomas Yankeelov, Ph.D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.
Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School. He holds the W.A. "Tex" Moncrief Jr., Simulation-Based Engineering and Sciences Professorship II – Computational Oncology and leads the Tumor Modeling Group in the university’s Institute for Computational Engineering and Sciences.
Yankeelov is the recipient of a distinguished $6 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT). He was The University of Texas’ first faculty member to hold positions in both the engineering and medical schools.
Yankeelov clinical research focuses on improving patient care by employing advanced imaging methods for the early identification, assessment and prediction of tumors and their response to therapy.
He has developed successful tumor-forecasting methods by combining imaging technologies with patient-specific data to build predictive, multi-scale biophysical models of tumor growth. His research emphasizes the importance of offering personalized therapies to cancer patients. Yankeelov is a fellow of the American Institute of Medical and Biological Engineers and has served on the editorial boards of scientific publications.
The overall goal of Yankeelov's clinical research is to improve patient care by employing advanced imaging methods for the early identification, assessment, and prediction of tumors' response to therapy. In order todo that, he has developed tumor forecasting methods by integrating advanced imaging technologies with patient-specific data and builds predictive, multi-scale biophysical models of tumor growth with the purpose of optimizing therapies for the individual cancer patient.
In this interview Yankeelov, Hofland and Portillo ask about computational oncology, what this is and how it fits in cancer treatment. They also ask about oncology models, what these models are trying to tell us, and how are they developed and how using these cancer models leads to a different way in looking at cancer.
Early Diagnosis of Solid Tumors: Using Liquid Biopsies to Detect and Track Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 41:01
In this Edition of the Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Amit Kumar, Ph.D, Chairman, President & Chief Executive Officer of ITUS Corporation Executive Chairman of Anixa Diagnostics Corporation
Dr. Kumar, is the inventor of the company’s Cchek™ technology for the early detection of tumor-based cancers and has been an investor, founder, director and CEO of several technology enterprises, both public and private.
In today’s program we talk with Dr, Kumar about cancer, the evolution of cancer diagnostics since the signing of the National Cancer Act and the start of the ‘War on cancer’ in the 1970’s and the development of new technologies designed to detect cancer early – with the clear advantage of being able to treat cancer sooner, which may lead to better results and offer a survival advantage.
In this Edition of the Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Amit Kumar, Ph.D, Chairman, President & Chief Executive Officer of ITUS Corporation Executive Chairman of Anixa Diagnostics Corporation
Dr. Kumar, is the inventor of the company’s Cchek™ technology for the early detection of tumor-based cancers and has been an investor, founder, director and CEO of several technology enterprises, both public and private.
In today’s program we talk with Dr, Kumar about cancer, the evolution of cancer diagnostics since the signing of the National Cancer Act and the start of the ‘War on cancer’ in the 1970’s and the development of new technologies designed to detect cancer early – with the clear advantage of being able to treat cancer sooner, which may lead to better results and offer a survival advantage.
Dr. Otis Brawley: Meeting the Challenge of Attacking Cancer from Every Angle
From Peter Hofland | Part of the The OncoZine Brief series | 39:38
This week in The Onco’Zine Brief: Peter Hofland, Ph.D and Sonia Portillo talk with Otis Brawley, MD, MACP the Chief Medical and Scientific Officer of the American Cancer Society.
Hofland and Portillo ask Dr. Brawley about the past, present, and future of the fight against cancer, including screening, diagnostics and treatment with novel, targeted drugs, and the role of the American Cancer Society in helping to prevent cancer.
This week in The Onco’Zine Brief: Peter Hofland, Ph.D and Sonia Portillo talk with Otis Brawley, MD, MACP the Chief Medical and Scientific Officer of the American Cancer Society.
Hofland and Portillo ask Dr. Brawley about the past, present, and future of the fight against cancer, including screening, diagnostics and treatment with novel, targeted drugs, and the role of the American Cancer Society in helping to prevent cancer.
In today’s interview they further address some of the most pressing issues in oncology today, such as cancer health disparities and access to healthcare in lower income areas, as well implementing healthy lifestyle choices and reducing cancer risk factors, in order to make the biggest impact possible on reducing the number of cancer-related deaths.
Hofland and Portillo also ask Dr. Brawley how to go about meeting the challenges in healthcare and find a solution for cancer health disparities, as well as how to educate the public on how to prevent and reduce risks of cancer in our daily lives - including the need of a healthy diet and to stop smoking.
This interview, took place during the annual meeting of the American Association of Cancer Research held April 14-18th, 2018, in Chicago, Illinois.
Dr. Joseph M. Connors: A New Frontline Treatment Option for Hodgekin Lymphoma
From Peter Hofland | Part of the The OncoZine Brief series | 39:59
In this Edition of The Onco'Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Joseph M. Connors, MD., FRCPC, Clinical Director, Center for Lymphoid Cancer (Retired 2018) and Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency.
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma, a clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (Adcetris; Seattle Genetics/Takeda).
In this Edition of The Onco'Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Joseph M. Connors, MD., FRCPC, Clinical Director, Centre for Lymphoid Cancer (Retired 2018) and Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma.
In this interview Dr. Connor talks about the some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) for patients with advanced classical Hodgkin Lymphoma.
The phase III ECHELON-1 study, was designed to evaluate brentuximab vedotin as part of a front-line chemotherapy regimen for previously untreated advanced classic Hodgkin lymphoma. The trial met its primary endpoint of modified progression-free survival in 2017. The latest data from the study was presented during the 2017 American Society of Hematology Annual Meeting & Expostion and simultaneous publication in The New England Journal of Medicine.
Now, brentuximab vedotin is an approved drug and commercially available in the United States. The ECHELON-1 trial was important for the approval by the FDA of a so called ‘fifth approval or line expansion’ of the drug.
Computational Oncology and Tumor Modeling - The Next Phase in Personalized Therapies for Cancer Patients.
From Peter Hofland | Part of the The OncoZine Brief series | 41:01
In this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Thomas Yankeelov, Ph.D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.
Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School. He holds the W.A. "Tex" Moncrief Jr., Simulation-Based Engineering and Sciences Professorship II – Computational Oncology and leads the Tumor Modeling Group in the university’s Institute for Computational Engineering and Sciences.
Yankeelov is the recipient of a distinguished $6 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT). He was The University of Texas’ first faculty member to hold positions in both the engineering and medical schools.
Yankeelov clinical research focuses on improving patient care by employing advanced imaging methods for the early identification, assessment and prediction of tumors and their response to therapy.
In this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Thomas Yankeelov, Ph.D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.
Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School. He holds the W.A. "Tex" Moncrief Jr., Simulation-Based Engineering and Sciences Professorship II – Computational Oncology and leads the Tumor Modeling Group in the university’s Institute for Computational Engineering and Sciences.
Yankeelov is the recipient of a distinguished $6 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT). He was The University of Texas’ first faculty member to hold positions in both the engineering and medical schools.
Yankeelov clinical research focuses on improving patient care by employing advanced imaging methods for the early identification, assessment and prediction of tumors and their response to therapy.
He has developed successful tumor-forecasting methods by combining imaging technologies with patient-specific data to build predictive, multi-scale biophysical models of tumor growth. His research emphasizes the importance of offering personalized therapies to cancer patients. Yankeelov is a fellow of the American Institute of Medical and Biological Engineers and has served on the editorial boards of scientific publications.
The overall goal of Yankeelov's clinical research is to improve patient care by employing advanced imaging methods for the early identification, assessment, and prediction of tumors' response to therapy. In order todo that, he has developed tumor forecasting methods by integrating advanced imaging technologies with patient-specific data and builds predictive, multi-scale biophysical models of tumor growth with the purpose of optimizing therapies for the individual cancer patient.
In this interview Yankeelov, Hofland and Portillo ask about computational oncology, what this is and how it fits in cancer treatment. They also ask about oncology models, what these models are trying to tell us, and how are they developed and how using these cancer models leads to a different way in looking at cancer.
The Importance of Oral Care – and the Link with Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 39:40
Today in the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Jim Ratcliff, CEO of Chairman of Rowpar Pharmaceuticals, the developer, manufacturer and marketer of best-in-class oral care products, sold under the CloSYS brand in Australia and the United States and under private label in Europe and India. In their interview Hofland and Portillo ask Dr.Ratcliff, about the importance of oral care – and the link with cancer.
Today in the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Jim Ratcliff, CEO of Chairman of Rowpar Pharmaceuticals, the developer, manufacturer and marketer of best-in-class oral care products, sold under the CloSYS brand in Australia and the United States and under private label in Europe and India. In their interview with Dr.Ratcliff, Hofland and Portillo ask about the importance of oral care – and the link with cancer.
Patients receiving treatment for cancer can experience a number of potential side effects in response to the treatment they receive. Most clinicians and patients are aware of the adverse events that can result from administration of certain chemotherapeutics. Without offering a complete list of side effects, known side effects include fatigue, alopecia – which affects many patients and is probably one of the most disturbing side effects, sometimes preventing people from accepting or refusing treatments based on chemotherapy. Other adverse effects include:
- Sexual dysfunction, which can be the result of chemotherapy and radiation therapy and affecting about 60% to 80% of patients receiving chemotherapy.
- Thrombocytopenia or low platelet count can affect clotting and cause bleeding.
- The gastrointestinal problems, such as nausea, vomiting, diarrhea, and constipation
And, one of the most serious side effects, cardiotoxicity, which can occur early or late in treatment. But one of the often forgotten side effects are cutaneous toxicities can include skin rash and mucositis. Mucositis is also one of the common side - is the painful inflammation and ulceration of the mucous membranes lining the digestive tract and may include mouth sores often affecting food intake.
Manon Rinsma: 13 Diamonds – Life Before Death from a Child’s Perspective.
From Peter Hofland | Part of the The OncoZine Brief series | 35:27
The Netherlands-born writer Manon Rinsma is the author of a new book called “13 Diamonds – Life before death from a Child’s Perspective.”
In her book, Rinsma writes about losing her mother at a very young age - something so traumatic that it completely changed how she viewed the world.
The Netherlands-born writer Manon Rinsma is the author of a new book called “13 Diamonds – Life before death from a Child’s Perspective.
In her book, Rinsma writes about losing her mother at a very young age - something so traumatic that it completely changed how she viewed the world. Rinsma's mother died of a form of brain cancer.
For her remaining family - finding an answer to the question "how do you help a child when a family member has cancer," was not only difficult, it was also one without a definite answer.How do you help a child:
- If the family member is a parent, father or mother, or a sibling, brother or sister.
- To understand a parent’s illness? An illness such as cancer - especially if there is no hope for a cure?
But in other cases, a patient may find out that he or she has cancer when the disease is quite advanced. As a result, they may not have a lot of time to deal with the effects on their family. If there is time, it may be good to help the child prepare for the loss of a parent. Preparing means to give them information and support. This helps them understand what to expect.
The pain of losing a parent may be worse if a child is not prepared. It may confuse them, hurt them, and make them angry that important facts – explained on the level of understanding of the child’s age – where not shared with them.
Children truly rely on parents to bring order and security into their lives. Parents help them understand the world around them and their place in it. But no matter how long cancer has been part of a patient’s life, it still can be very hard for him or her and their loved ones to think about all the things that go along with the end of life. The remaining partner may understand what this means.But what does it mean for a child to lose a parent?
What are the psychosocial effects – now and later in life? Especially if this is a parent and the child is still young?
In this edition of The Onco'Zine Brief we will try to answer some common questions parents have and help patients take important steps to prepare a child to cope with death. Although it’s not possible to control the reality of dying, it is possible to make a real difference in how a child manage it … and go on with his or her lives after a parent is gone.
Rinsma’s book is proof of all of this.
Addressing Key Challenges in Cancer Treatment: Cancer Health Disparities
From Peter Hofland | Part of the The OncoZine Brief series | 38:12
Today in The Onco’Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Michael Caligiuri, MD, a renowned physician-scientist known for his work in immunology that is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma.
The Interview was recorded during the 2018 annual meeting of American Association for Cancer Research (AACR) held April 14-18th, 2018 in Chicago, Illinois.
Dr. Caligiuri is the president and physician-in-chief of City of Hope National Medical Center in Duarte, California. Founded in 1913, City of Hope is one of only 49 comprehensive cancer centers in the United States, as designated by the National Cancer Institute.
Before joining City-of-Hope, Dr. Caligiuri was the director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio He was also the 2017 president of the American Association for Cancer Research – AACR – which is the world's oldest and largest professional association related to cancer research.
Today in The Onco’Zine Brief Peter Hofland and Sonia Portillo talk with Dr. Michael Caligiuri., MD
The Interview was recorded during the 2018 annual meeting of American Association for Cancer Research (AACR) held April 14-18th, 2018 in Chicago, Illinois.
Michael A. Caligiuri is a renowned physician-scientist known for his work in immunology that is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. To date over 1,500 cancer patients have been treated on clinical protocols that have originated from the Dr. Caligiuri laboratory.
Dr. Caligiuri is the president and physician-in-chief of City of Hope National Medical Center in Duarte, California. Founded in 1913, City of Hope is one of only 49 comprehensive cancer centers in the United States, as designated by the National Cancer Institute. The center’s main campus is located just northeast of Los Angeles, with additional locations across Los Angeles, Ventura, Riverside, Orange and San Bernardino counties, and focuses on the treatment of patients with cancer, diabetes and other life-threatening illnesses.
Before joining City-of-Hope, Dr. Caligiuri was the director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio He was also the 2017 president of the American Association for Cancer Research – AACR – which is the world's oldest and largest professional association related to cancer research.
Based in Philadelphia, Pennsylvania, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the cause, prevention, diagnosis, and treatment of cancer.
Last year, following his appointment as the AACR president, Peter Hofland and Sonia Portillo sat down with Dr. Caligiuri to ask him about his passion, his hopes, his drive and what he wanted to accomplish during his tenure as president of the American Association for Cancer Research during 2017 and the beginning of 2018.
This year, at the end of his tenure as president of the AACR, we again had the opportunity to sit down with him … This time Hofland and Portillo asked him about his experience, and how he was able to help solve some of the key challenges he had noted before. Dr. Caligiuri has been actively involved with the AACR since 1990, serving as a member, and more recently, chairperson of the Publications Committee and a member of the Clinical and Translational Cancer Research Committee, among other things.
One of Dr. Caligiuri main concerns – indicated in our interview in 2017 - is the problem of Cancer health disparities that represent a major public health problem in our country.
By promoting the exchange of novel ideas and information between the AACR and a wide range of professionals from academia, industry, government, and the community, Dr. Caligiuri hoped to drive a movement to help eliminate the disparities and harness the potential and maximize the many opportunities for bringing research on health disparities from bench to bedside or community, and back again.
As part of that effort, he wanted, during his tenure as president of the AACR, bring together scientists and other professionals working in a variety of disciplines to discuss the latest findings in the field and to stimulate the development of new research in cancer health disparities.
And it must be said… One of the challenges society faces today is how to ensure that everyone benefits equally from the groundbreaking advances in cancer treatment and prevention.
Cancer health disparities are indeed a huge problem.
For example, African-Americans have the shortest survival for most cancers compared with those in other racial and ethnic groups in the United States. Hence, there is a large unmet need to do more to understand the reasons for disparities as well as ways to address them.
The issue of disparities is a complex, multifactorial problem that involves genetic, behavioral, and socio-economic factors, among others, and it will require a multifaceted, evidence-based approach to solving the problem.
In our interview, Dr. Caligiuri is addressing some of the problems as well as what he and the AACR hopes to accomplish in the upcoming years.
Transforming Cancer to a Treatable Disease.
From Peter Hofland | Part of the The OncoZine Brief series | 35:53
In this edition of The Onco’Zine Brief Peter Hofland and Sonia Portillo are talking with Elizabeth M. Jaffee, MD, the 2018 - 2019 president of the American Association for Cancer Research (AACR).
Dr. Jaffee’s, who's research is focused on the development of immune based therapies for pancreatic and breast cancers, is the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. She is also the leader of the Stand Up To Cancer (SU2C)-Lustgarten Foundation Dream Team: Transforming Pancreatic Cancer to a Treatable Disease.
In their interview recorded during the annual meeting of the AACR, held April 14-18th, 2018 in Chicago, Illinois, Hofland and Portillo asked Dr. Jaffee about her work, her expectations and her plans as the current president of the AACR.
- Playing
- Transforming Cancer to a Treatable Disease.
- From
- Peter Hofland
This week in The Onco’Zine Brief Peter Hofland and Sonia Portillo are talking with Elizabeth M. Jaffee, MD, the 2018 - 2019 president of the American Association for Cancer Research (AACR).
Dr. Jaffee’s, who's research is focused on the development of immune based therapies for pancreatic and breast cancers, is the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. She is also the leader of the Stand Up To Cancer (SU2C)-Lustgarten Foundation Dream Team: Transforming Pancreatic Cancer to a Treatable Disease.
In their interview during the annual meeting of the AACR, held April 14-18th, 2018 in Chicago, Illinois, Hofland and Portillo asked Dr. Jaffee about her work, her expectations and her plans as the current president of the AACR.
They also asked her about the importance of clinical trials and patient participation in these trials as being a key step towards progress in oncology.
Today only about 5% of cancer patients are expected to participate in a trial. The fact that only a limited number of patients participate in a clinical trial, goes beyond the (un)willingness of patients to participate, but has a lot to do with the fact that most patients have to travel to the nation’s major research hospitals in order to participate.
Another concern is that many patients may not realize that when they participate in a clinical trial, they will get that same level of care that they would with cancer treatments outside of a trial. Hence, Dr. Jaffee emphasizes that it is not only important to make sure that patients understand the difference between medical treatment and clinical research, but that it is also crucial to improve accessibility to clinical trials.
A Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy
From Peter Hofland | Part of the The OncoZine Brief series | 39:00
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Col. James E. Williams who, during the annual meeting of the American Association for Cancer Research (AACR), held April 14 - 18, 2018 in Chicago, Ill, received the organization's Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.
Williams, a retired Army colonel who served in the Vietnam War, was diagnosed with prostate cancer in 1991.
After he beat the disease, he embarked on a passionate effort to educate men about the disease. Williams is an inspiration and a role model - not only to other cancer survivors, but also to the scientific community at large.
As a steadfast passionate advocate Williams increased funding and research dedicated to men’s health issues, with an emphasis on prostate cancer. His selfless efforts are also instrumental in improving outcomes for racial and ethnic minorities and the medically underserved.
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Col. James E. Williams who, during the annual meeting of the American Association for Cancer Research (AACR), held April 14 - 18, 2018 in Chicago, Ill, received the organization's Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.
Each year, the American Association for Cancer Research (AACR) presents Special Recognition Awards to four individuals whose work made extraordinary contributions to the organization’s mission to accelerate the prevention and cure of all cancers through research, education, communication, and collaboration.
These AACR Awards recognize groundbreaking, innovative work across the entire cancer community, and they reflect a wide range of contributions to cancer science and medicine. This year’s award recipients, Anna D. Barker, PhD; C. Kent Osborne, MD; Phillip A. Sharp, PhD; and Col. James E. Williams, truly represent meritorious work in research, patient care, policymaking, and advocacy.
Williams, a retired Army colonel who served in the Vietnam War, was diagnosed with prostate cancer in 1991.
After he beats the disease, he embarked on a passionate effort to educate men about the disease.
His advocacy efforts include serving as a member of the Editorial Advisory Board of the AACR’s Cancer Today magazine; serving as Chairman of the Board of The Intercultural Cancer Council (ICC); serving as Chairman of the Pennsylvania Prostate Cancer Coalition; participating on the Patient Advocacy Committee of the Alliance for Clinical Trials in Oncology; and serving as a Board member of the Alliance for Prostate Cancer Prevention. Williams is an inspiration and a role model - not only to other cancer survivors, but also to the scientific community at large.
As a steadfast passionate advocate Williams increased funding and research dedicated to men’s health issues, with an emphasis on prostate cancer. His selfless efforts are also instrumental in improving outcomes for racial and ethnic minorities and the medically underserved.
A Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy
From Peter Hofland | Part of the The OncoZine Brief series | 39:00
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Col. James E. Williams who, during the annual meeting of the American Association for Cancer Research (AACR), held April 14 - 18, 2018 in Chicago, Ill, received the organization's Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.
Williams, a retired Army colonel who served in the Vietnam War, was diagnosed with prostate cancer in 1991.
After he beat the disease, he embarked on a passionate effort to educate men about the disease. Williams is an inspiration and a role model - not only to other cancer survivors, but also to the scientific community at large.
As a steadfast passionate advocate Williams increased funding and research dedicated to men’s health issues, with an emphasis on prostate cancer. His selfless efforts are also instrumental in improving outcomes for racial and ethnic minorities and the medically underserved.
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Col. James E. Williams who, during the annual meeting of the American Association for Cancer Research (AACR), held April 14 - 18, 2018 in Chicago, Ill, received the organization's Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.
Each year, the American Association for Cancer Research (AACR) presents Special Recognition Awards to four individuals whose work made extraordinary contributions to the organization’s mission to accelerate the prevention and cure of all cancers through research, education, communication, and collaboration.
These AACR Awards recognize groundbreaking, innovative work across the entire cancer community, and they reflect a wide range of contributions to cancer science and medicine. This year’s award recipients, Anna D. Barker, PhD; C. Kent Osborne, MD; Phillip A. Sharp, PhD; and Col. James E. Williams, truly represent meritorious work in research, patient care, policymaking, and advocacy.
Williams, a retired Army colonel who served in the Vietnam War, was diagnosed with prostate cancer in 1991.
After he beats the disease, he embarked on a passionate effort to educate men about the disease.
His advocacy efforts include serving as a member of the Editorial Advisory Board of the AACR’s Cancer Today magazine; serving as Chairman of the Board of The Intercultural Cancer Council (ICC); serving as Chairman of the Pennsylvania Prostate Cancer Coalition; participating on the Patient Advocacy Committee of the Alliance for Clinical Trials in Oncology; and serving as a Board member of the Alliance for Prostate Cancer Prevention. Williams is an inspiration and a role model - not only to other cancer survivors, but also to the scientific community at large.
As a steadfast passionate advocate Williams increased funding and research dedicated to men’s health issues, with an emphasis on prostate cancer. His selfless efforts are also instrumental in improving outcomes for racial and ethnic minorities and the medically underserved.
An interview with Neil Canavan: How Scientists Unleash the Immune System to Kill Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 42:10
In this edition of The Onco’Zine Brief, Sonia Portillo interviews Neil Canavan, about the people involved in developing novel, advanced – and sometimes – highly personalized - anti-cancer treatments.
Canavan is a veteran journalist with more than 20 years of experience reporting on science and medicine. For the last 5 years he has reported exclusively on issues related to drug development in cancer.
In his new book – A Cure Within - published by Cold Spring Harbor Laboratory Press, Neil Canavan writes about the power of the immune system and his reasons and motivation to write the book.
Canavan explains how the way we treat cancer is about to change forever. He writes about a revolution--and it is precisely that--which was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer.
Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient's own immune system will kill the tumor.
In this edition of The Onco’Zine Brief, Sonia Portillo interviews Neil Canavan, about the people involved in developing novel, advanced – and sometimes – highly personalized - anti-cancer treatments.
Canavan is a veteran journalist with more than 20 years of experience reporting on science and medicine. For the last 5 years he has reported exclusively on issues related to drug development in cancer.
In his new book – A Cure Within - published by Cold Spring Harbor Laboratory Press, Neil Canavan writes about the power of the immune system and his reasons and motivation to write the book.
Canavan explains how the way we treat cancer is about to change forever. He writes about a revolution--and it is precisely that--which was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer.
Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient's own immune system will kill the tumor.
Based entirely on interviews with the investigators, Canavan tells the story of the pioneers of immuno-oncology. It’s a story of failure, resurrection, and success. It’s a story about science, it’s a story about discovery, and intuition, and cunning. It’s a peek into the lives and thoughts of some of the most gifted medical scientists on the planet.
This is not a textbook. This is a life book. This technology will save/is saving lives, and the book celebrates the living, breathing, thinking, charming, arrogant, funny, obstinate, amazing human beings who are making immuno-oncology happen.
Advancing Treatment for Patients with Triple Negative Breast Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 43:00
In this edition of The Onco’Zine Brief, recorded during the Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, June 1 - 5, 2018, Peter Hofland and Sonia Portillo talk with Michael Pehl, President and Chief Executive Officer of Immunomedics, a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC).
SU2C: 10 years of Watershed Moments in Cancer Research
From Peter Hofland | Part of the The OncoZine Brief series | 41:00
In this edition of The Onco'Zine Brief on PRX, Peter Hofland and Shelly Reynolds talk with founding members of the managements teams of Stand Up To Cancer (SU2C) and The Lustgarten Foundation, including Dr. Sung Poblete, Kerri Kaplan, Dr. Phil Sharp and Dr. Dave Tuveson.
In this edition of The Onco'Zine Brief on PRX, Peter Hofland and Shelly Reynolds talk with for the managements teams of Stand Up To Cancer (SU2C) and The Lustgarten Foundation, including Dr. Sung Poblete, Kerri Kaplan, Dr. Phil Sharp and Dr. Dave Tuveson.
Earlier this year, Stand Up To Cancer (SU2C) and The Lustgarten Foundation announced today at the Annual Meeting of the American Association for Cancer Research, SU2C’s Scientific Partner, that they are entering into a formal strategic partnership to drive research to improve outcomes for pancreatic cancer patients. The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients who desperately need better treatments. The initial funding commitment will be $25 million.
Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson
From Peter Hofland | Part of the The OncoZine Brief series | 40:53
In this edition of The OncoZine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company specialized in the development of Antibody-drug Conjugates. This Interview was recorded during the annual pharmaceutical industry meeting, CPhI Worldwide, held October 9 – 11, 2018 in Madrid, Spain.
This edition was a co-production with ADC Review | the Journal of Antibody-drug Conjugates - www.ADCreview.com and Onco’Zine - www.oncozine.com
- Playing
- Revolutionizing the Manufacturing of ...
- From
- Peter Hofland
National Colorectal Cancer Awareness Month: Prevention, Diagnosis and Treatment (Part 1)
From Peter Hofland | Part of the The OncoZine Brief series | 48:03
In this edition of The Onco’Zine Brief Peter Hofland talk with Dr. Paul Berggreen and Dr. Daniel Jondle, both from Arizona Digestive Health, in Phoenix, Arizona, about Colorectal Cancer.
In this edition of The Onco’Zine Brief Peter Hofland talk with Dr. Paul Berggreen and Dr. Daniel Jondle, both from Arizona Digestive Health, in Phoenix, Arizona, USA, about Colorectal Cancer.
National Colorectal Cancer Awareness Month 2019 (Part 2)
From Peter Hofland | Part of the The OncoZine Brief series | 45:48
In the second part of a 3-part series about colorectal cancer developed in collaboration with the online journal, OncoZine at www.oncozine.com, Peter Hofland, PhD. talks with Paul J. Berggreen, MD and Daniel M. Jondle, MD, both from Arizona Digestive Health, in Phoenix, Arizona, and Sukhdeep S Padda, MD from Arizona Gastrointestinal Associates and Arrowhead Gastroenterology Associates, in Glendale, Arizona.
In the second part of a 3-part series about colorectal cancer, developed in collaboration with the online journal OncoZine at www.oncozine.com, Peter Hofland, PhD. talks with Paul J. Berggreen, MD and Daniel M. Jondle, MD, both from Arizona Digestive Health, in Phoenix, Arizona, and Sukhdeep S Padda, MD from Arizona Gastrointestinal Associates and Arrowhead Gastroenterology Associates, in Glendale, Arizona.
Colorectal Cancer is also the second leading cause of death from cancers that affect both men and women. According to the American Cancer Society, the overall lifetime risk of developing colorectal cancer is: about 1 in 22 for men and 1 in 24 for women. But in many cases the disease is preventable. And Prevention starts with awareness and accurate knowledge
This Month is National Colorectal Cancer Awareness Month.
Doctors recommend screening for healthy people with no signs or symptoms in order to look for early evidence of Colorectal Cancer, which is also known as colon cancer.
Finding colorectal cancer at its earliest stage makes it easier to treat. Overall, screening has been shown to reduce the risk of dying of colorectal; cancer.
People with an average risk of colorectal cancer should consider screening beginning at age 50.
But if you have an increased risk, such as a family history of colorectal cancer, you should consider screening sooner.
In this episode listen to the experts when they discuss the ‘Gold Standard’ in screening for Colorectal Cancer as well as alternatives, share information about the latest treatment options and talk about the importance of clinical trials.
A Bold Approach to Identify New and Effective Therapies for Malignant Brain Tumors
From Peter Hofland | Part of the The OncoZine Brief series | 48:03
In this edition of The Onco’Zine Brief Peter Hofland, PhD talks with Nader Sanai, MD, an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain.
Sanai is the director of the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix, Arizona. He is also the principal architect of the Center’s accelerated clinical trials program, the largest in the word.
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine.
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.
Cannabinoid-based Drug Discovery and Development Designed to Benefit Cancer Patients
From Peter Hofland | Part of the The OncoZine Brief series | 48:15
This week in The Onco’Zine Brief Peter Hofland, Ph.D talks with Guy Chamberland, M.Sc., Ph.D, about medicinal cannabis.
Chamberland, is a Master Herbalist as well as Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, a biopharmaceutical company developing cannabinoid-based drugs.
Tetra Bio-Pharma has a clinical development program aimed at bringing novel drugs and treatments to patients and their healthcare providers.
Tetra Bio-Pharma has a clinical development program aimed at bringing novel drugs and treatments to patients and their healthcare providers.
To do this, the Company has several subsidiaries that are engaged in the development of Bio Pharmaceutical drugs and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis-use with the supporting scientific validation and safety-data required by federal and national regulators, physicians and insurance companies.
A New Combination Therapy may help Stop Triple Negative Breast Cancer from Spreading
From Peter Hofland | Part of the The OncoZine Brief series | 44:37
In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Salman M. Hyder, Ph.D.
Dr. Hyder is Professor in Tumor Angiogenesis and professor of Biomedical Sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at the university of Missouri, in Columbia, Missouri.
Together with a team of researchers Dr. Hyder found that a combination drug therapy, reduces the spread of triple negative breast cancer to other locations of the body by 50%.
In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Salman M. Hyder, Ph.D
Dr. Hyder is Professor in Tumor Angiogenesis and professor of Biomedical Sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at the university of Missouri, in Columbia, Missouri.
Together with a team of researchers Dr. Hyder found that a combination drug therapy, reduces the spread of triple negative breast cancer to other locations of the body by 50%.
Triple negative breast cancer
A breast cancer cell is like a house with three locks on the front door. Keys, or receptors, allow drugs to unlock the door and kill the cell. However, in triple-negative breast cancer, these keys are absent, thereby resulting in few options for drug therapy.
Until now.
A protein called p53 suppresses and kills cancer in people. However, in contrast - a defective, mutant form of p53 helps cancer cells grow and multiply.
p53, also known as TP53 or tumor protein is a gene that codes for a protein that regulates the cell cycle and, as a result, functions as a tumor suppression. p53 is important for cells in multicellular organisms to suppress cancer.
Lacking treatment options
Triple negative breast cancer lacks ways to treat the cancer with hormone therapies or anti-HER2 targeted therapies.
The most common types of receptors fueling most breast cancer growth – estrogen, progesterone, and the HER-2/neu gene – are not present in this type of cancer.
This means that while other forms of breast cancer in which breast cancer cells have tested positive for hormone epidermal growth factor receptor 2 (HER-2), estrogen receptors (ER), and progesterone receptors (PR) and can be treated with common treatments like hormone therapy and drugs that target estrogen, progesterone, and HER-2, these drugs are ineffective in Triple Negative Breast cancer.
While chemotherapy can work well in Triple Negative Breast cancer – and a patient may even respond better to chemotherapy than some other types of breast cancer - these drugs are toxic, and non-specific.
Metastasis
Research has shown that most people who die as the result of breast cancer, in particular women with triple-negative breast cancer, do so following metastasis, or spread of the cancer to other organs in the body.
Dr. Hyder and his team wanted to see if a new combination therapy could provide a new, non-toxic targeted approach for treatment.
In a preclinical study with two previously discovered drugs —one that restores the p53 protein’s ability to kill cancer cells and another that targets the blood vessels in order to kill cancer cells — they observed an effect on metastatic triple negative breast cancer.
And according to the researchers, the results are promising.
Dr. Hyder noted that the cancer did not spread as fast when both drugs were given separately, and a little more with the combination of the two agents.
The two investigational drugs, APR-246 and 2aG4, are currently in clinical trials.
Researchers hope that these findings will help enhance personalized treatment for breast cancer by reducing existing cancer cells and preventing the spread of the cancer to other parts of the body.
How Proper Pain Management Helps Improve Health Related Quality of Life
From Peter Hofland | Part of the The OncoZine Brief series | 47:44
In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Lisa Stearns, MD.
Dr. Stearns, an anesthesiologist who received her medical degree from University of Nebraska College of Medicine, is the founder and medical director of Center for Pain and Supportive Care, in Phoenix, Arizona.
An internationally recognized Interventional Pain Specialist, board certified in hospice and palliative medicine and pain management, Dr. Stearns’ passion for changing the face of acute and chronic pain-treatment is evidenced by her ongoing care for her patients and her active research to find a better way to manage pain.
In addition to her work at the Center for Pain and Supportive Care, Dr. Stearns has authored numerous research articles and frequently speaks at medical society meetings around the world to share her knowledge and her passion to help her patients.
In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Lisa Stearns, MD.
Dr. Stearns, an anesthesiologist who received her medical degree from University of Nebraska College of Medicine, is the founder and medical director of Center for Pain and Supportive Care, in Phoenix, Arizona.
An internationally recognized Interventional Pain Specialist, board certified in hospice and palliative medicine and pain management, Dr. Stearns’ passion for changing the face of acute and chronic pain-treatment is evidenced by her ongoing care for her patients and her active research to find a better way to manage pain.
And patients often experience pain from surgery - from tumors pressing on bones, nerves, or organs and from chemotherapy and radiation.
But each of these kinds of pain can be controlled and kept at a bearable level.
Dr. Sterns and her co-workers at the Center for Pain and Supportive Care work with cancer patients to develop a unique pain-management and rehabilitation-plan, based on a patient’s type of cancer.
Using a palliative care model Dr. Stearns brings together a team of healthcare professionals to help create the best possible quality of life for her patients and their overall health and wellness.
An escalating battle
As a nation we battle an escalating opioid-overdose crisis – driven by synthetic opioids such as fentanyl but also tramadol and other drugs.
Based on the latest data, this crisis claims more than 100 lives per day.
In their response to this crisis, the government has enacted tougher new laws and regulations on opioid prescribing.
These laws are, however well-intentioned, also restricting access to opioids for cancer patients. At the same time, opioid-use, has an addiction stigma among many patients with cancer.
But, how common are opioid-related deaths in patients with cancer?
To answer this question, researchers at the Duke University School of Medicine conducted a retrospective review of death certificate data from the National Center of Health Statistics, which provides information about the cause of death as well as and the contributing factors.
The researchers looked at data from deaths due to opioids from 2006 to 2016.
They calculated the opioid death incidence from the estimated cancer survivor population, as well as the total population of the United States.
The researchers found that from 2006 to 2016, about 900 deaths were related to opioids in patients with cancer.
However, this was compared with about 200,000 deaths in the non-cancer population.
Opioid deaths in both groups did increase over time, from about 5 to almost 9 per 100,000 people in the general population and 0.5 to 0.7 per 100,000 in the cancer patient population.
The researchers noted that in real, practical terms, the volume of overdose deaths in patients with cancer is very small. It increased from 59 patients in 2006 to 102 patients in 2016.
The researchers involved in this study found that deaths from opioid abuse, as the primary cause of death, is about 10 times less likely to occur in patients with cancer.
Healthcare professionals like Dr. Stearns are committed to help cancer patients with pain management designed to improve the individual’s health related quality of Life.
Augmenting the Immune System’s Natural Ability to See and Eliminate Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 48:11
In this edition of The Onco’Zine Brief Peter Hofland talks with Mr. Isaac Israel the Chief Executive Office of Kitov Pharma, a pharmaceutical drug development company developing new options to treat osteoarthritis pain and hypertension simultaneously, as well as novel anticancer drugs.
The company is developing an investigational drug called NT-219, a novel small molecule drug designed to targets two signal proteins that are part of an anti-cancer drug resistance mechanism.
Based on recent findings, Kitov researchers demonstrated that NT-219 binds directly to the two proteins. In previous preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was demonstrated.
In this edition of The Onco’Zine Brief Peter Hofland talks with Mr. Isaac Israel the Chief Executive Office of Kitov Pharma, a pharmaceutical drug development company developing new options to treat osteoarthritis pain and hypertension simultaneously, as well as novel anticancer drugs.
The company is developing an investigational drug called NT-219, a novel small molecule drug designed to targets two signal proteins that are part of an anti-cancer drug resistance mechanism.
Based on recent findings, Kitov researchers demonstrated that NT-219 binds directly to the two proteins. In previous preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was demonstrated.
The Future of Cancer Treatment
Immuno-oncology is increasingly recognized as the future in cancer therapy and many immuno-oncology candidates, including NT-219, have been identified and are currently being tested in preclinical studies or the clinic.
Founded upon the key principles of the immune response, Immuno-Oncology research seeks to understand how the body’s natural defenses, can be leveraged to empower antitumor immunity.
Immuno-oncology is different than traditional cancer treatments.
It works by augmenting the immune system’s natural ability to see and eliminate cancer cells much in the same way it protects us against infection from viruses and bacteria.
As a living, dynamic system, the immune system is able to detect cancer anywhere in the body, which is especially important in treating patients with cancers that have spread or metastasized to other organs.
Recent clinical success has resulted in the approval of a number of novel immuno-oncology therapies, both alone and in combination with other treatments, for nearly 20 types of cancer, including advanced solid tumor and blood cancers as well as cancers with a specific genetic defect resulting in a high frequency of mutation, regardless of tissue type.
In bladder cancer, melanoma, and certain types of lung cancer, these immuno-oncology therapies have received approval by the Unites States Food and Drug Administration as first-line treatment, replacing or, in the case of combination therapies, improving conventional treatments like chemotherapy.
Immuno-oncology therapies are also FDA-approved to treat some patients for whom prior treatments were ineffective.
Today, clinical trials are ongoing to test the benefits of Immuno-oncology agents in many other types of cancer.
Beyond the Emergence of Targeted Therapies and the Treatment of Bladder Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 47:25
This week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019.
In this episode Peter Hofland talks with a Adil Akhtar, MD, an Oncologist and Palliative Care Expert, Associate Professor, Department of Medical Oncology & Hematology at the Oakland University-William Beaumont School of Medicine. He is also director, of Inpatient Clinical Operations at the Karmanos-McLaren Oakland Cancer Center in Michigan and Chief, Division of Palliative & End of Life Care, Michigan Health Professionals.
This week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019.
In this episode Peter Hofland talks with a Adil Akhtar, MD, an Oncologist and Palliative Care Expert, Associate Professor, Department of Medical Oncology & Hematology at the Oakland University-William Beaumont School of Medicine. He is also director, of Inpatient Clinical Operations at the Karmanos-McLaren Oakland Cancer Center in Michigan and Chief, Division of Palliative & End of Life Care, Michigan Health Professionals.
Bladder Cancer
Bladder cancer is the sixth most common cancer in the U.S., with 81,000 new cases diagnosed each year, and 17,000 deaths annually. The most common type of bladder cancers arises from the transitional epithelium and are called transitional cell or urothelial carcinomas.
Typically, the patient’s choice of treatment will depend on the invasion of the muscle layer of the bladder, and has traditionally involved surgery, chemotherapy and/ or radiation treatment.
Earlier this year, a new drug called erdafitinib, marketed as Balversa® (The Janssen Pharmaceutical Companies of Johnson & Johnson) was approved by the United States Food and Drug Administration.
This drug is part of a new crop of potentially life-saving drugs is radically changing what the future of cancer care looks like— and improving outcomes for patients suffering from some of the most prevalent cancers. In the United States erdafitinib, the first-ever personalized treatment for bladder cancer, is one of these drugs.
Immunotherapy is also increasingly used in advanced stages, but until now there have been no approved targeted agents for bladder cancer.
The way physicians approach the disease is rapidly transforming. Tailoring treatment in accordance with the patient’s precise genetic mutation or biomarker is quickly becoming the new standard in cancer care. This is in contrast to the traditional way of thinking in which cancer was specifically focusing on an organ or body part (i.e. brain cancer, bladder cancer, breast cancer, etc.).
The use of targeted therapies in bladder cancer is still an emerging field of research— but the apparent success of erdafitinib showcases the promise they may hold.
Palliative Care Expert.
In addition to being an oncologist, Dr. Akhtar’s medical specializations also include, palliative care and end of life/hospice care. He believes that everyone has a right to decide what kind of medical care they want. He is very passionate about the healthcare living will and advance care planning. He has founded Advance Care Now to help people understand and make decisions about advance care planning.
Patients Taking Back Control of their Own Healthcare Information
From Peter Hofland | Part of the The OncoZine Brief series | 46:02
This week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019. In this episode Peter Hofland talks with Eugene Luskin, Chief Executive Officer of Redmond, Washington-based Vyrty.
As part of a growing push to let patients control and manage their own medical history, Luskin’s Vyrty has launched a mobile app called Sync.MD that is designed by healthcare professionals to lets users – patients - store and share their own medical records with doctors. The app is a Personal Health Records (PHR-) system operated directly on behalf of and by patients, making them the real guardians of their health data.
This week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019. In this episode Peter Hofland talks with a Eugene Luskin, Chief Executive Officer of Redmond, Washington-based Vyrty.
As part of a growing push to let patients control and manage their own medical history, Luskin’s Vyrty has launched a mobile app called Sync.MD that is designed by healthcare professionals to lets users - patients - store and share their own medical records with doctors. The app is a Personal Health Records (PHR-) system operated directly on behalf of and by patients, making them the real guardians of their health data.
As the custodian of their own healthcare information, patients can keep all their health data in one place and easily share it with health professionals to streamline registrations, referrals, and coordinated care. For patients, it takes just seconds to sync with any computer in a fully secure and encrypted process.
For healthcare professionals, Sync.MD makes it easy to share data and information in real-time (as required by HIPAA) with anyone involved in providing or assisting their your patient’s healthcare needs.
The web-based interface grantees easy accessing, uploading, or downloading of documents and does no require the installation of complex software. The system is also easier and more affordable than large electronic health records (EHR) systems developed by the likes of Epic Systems, Cerner and Allscripts.
With multiple challenges in accessing and sharing data via legacy EHR-system as a result of remaining interoperability problems, Sync.MD-developers have created an easy to integrated, and low-costs, system designed to benefit both patients and doctors.
ASCO 2019: The Courage and Expertese to Outsmart Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 47:42
Updates from ASCO 2019 - the Annual Meeting of the American Society of Clinical Oncology (Part 3)
- Anna Protopapas, the president and Chief Executive Office of Mersana Therapeutics, a clinical stage biotech company developing antibody-drug conjugates – a very specific kind of targeted anti-cancer drug
- Eliran Malki, the Chief executive officer of BELONG.life, the world’s largest social network for cancer patients and caregivers designed to gain a better understanding of the cancer patient journey, with the goal of optimizing treatment and outcomes.
- Dr. Rod Humerickhouse, asset strategy leader oncology at AbbVie, a highly focused research-driven biopharmaceutical company. As a major developer of anticancer drugs, AbbVie’s oncology scientists understand that outsmarting cancer takes a potent combination of courage, scientific expertise and strategy.
A Commitment to Innovation in Medicines, Medical Devices and Healthcare Technologies
From Peter Hofland | Part of the The OncoZine Brief series | 47:54
In this episode of The Onco'Zine Brief, just ahead of the Arizona Bioscience Week held in Phoenix, AZ from September 30 to October 4, 2019, Peter Hofland talks with 3 experts’ biotech entrepreneurs about their company, cancer and cancer treatment and how Arizona’s bioscience industry is truly committed to discovering, developing and delivering innovative medicines, medical devices and healthcare technologies that make life better for people in Arizona and around the world.
This edition of the Onco'Zine Brief was recorded at the Center for Entrepreneurial Innovation (CEI) in Phoenix, AZ.
- Patti DuBois, Assistant Executive Director of the Center for Entrepreneurial Innovation (CEI), a comprehensive business incubator which provides specific services, space and support critical to the development of early-stage and startup companies,
- Don Weber, President & Chief Executive Officer of Beacon Biomedical, a medical diagnostic development and an accredited laboratory services company providing easy, accurate and affordable blood tests for earlier cancer detection, and
- David Richardson, Chief Executive Officer and a founding member of bioSyntagma, a company combining artificial intelligence or AI with medicine to assess so called Molecular Fingerprints to predict treatment combinations in both drug discovery and diagnostics, leading to the development of personalized or targeted therapies and companion diagnostics.
The PRECEDE Study: Transforming the Early Detection and Prevention of Pancreatic Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 48:17
A new, international collaborative initiative called The Pancreatic Cancer Early Detection or PRECEDE Consortium, which includes more than 35 leading academic medical centers across the globe, wants to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10 percent today to 50 percent within the next 10 years.
Pancreatic Cancer. According to the American Cancer Society, pancreatic cancer is one of the deadliest cancers, with a 5-year survival rate of just 10 percent. In the United States about 70% of patients diagnosed with this disease die within 1 year of diagnosis. Globally, pancreatic cancer is the 7th leading cause of death. Unfortunately, both the incidence and mortality of pancreatic cancer are still increasing, while the incidence and death from many other cancers, is declining.
A new, international collaborative initiative called The Pancreatic Cancer Early Detection or PRECEDE Consortium, which includes more than 35 leading academic medical centers across the globe, wants to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10 percent today to 50 percent within the next 10 years.
In this episode of The Onco'Zine Brief Peter Hofland, Ph.D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Director, Pancreatic Cancer Center and Associate Director, Translational Research, Perlmutter Cancer Center.
Hofland also talks with Tom Schoenherr, the Chief Executive Officer of Ambry Genetics, one of the participating industry partners of the PRECEDE program.In today’s episode Simeone, Schoenherr, and Hofland talk about Pancreatic Cancer and a new, international collaborative initiative called The Pancreatic Cancer Early Detection or PRECEDE Consortium, which includes more than 35 leading academic medical centers across the globe. The PRECEDE Consortium wants to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10 percent today to 50 percent within the next 10 years
In addition to academic centers, the PRECEDE Consortium includes industry partners who bring their expertise and resources in genetic testing, pathology, and imaging as well as in information technology to support the program; to determine who is at an elevated risk for developing pancreatic cancer, define that risk, and invite those with a higher risk to participate in a state-of-the-art clinical screening program.
The PRECEDE Consortium analyzes and standardizes data curated through an integrated diagnostics platform called LATTICE™, a platform that runs on Amazon Web Services or AWS. LATTICE uses Amazon HealthLake, a HIPAA-eligible service that helps organizations store, transform, query, and analyze health data, and will help researchers and clinicians gain new genomic insights for detecting and preventing pancreatic cancer.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit Onco'Zine to download our Media Kit or visit Patreon to support the program.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine
A Promising Treatment Option for Patients Diagnosed with Head-and-neck Cancer
From Peter Hofland | Part of the The OncoZine Brief series | 48:50
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Eyal Talor, Ph.D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmune diseases, and infectious diseases. In today’s program, Hofland and Talor are talking about one of these agents, an investigational drug called leukocyte interleukin, or Multikine®
Mismatched Unrelated Donors: A Key to Erasing the Gap in Donor Availability in HCT
From Peter Hofland | Part of the The OncoZine Brief series | 41:50
In the 100th episode of the Onco’Zine Brief, Peter Hofland talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.
Hofland and Spellman talk about bone-marrow transplants.
In the 100th episode of the Onco'Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.
In the program today Hofland and Spellman talk about bone-marrow transplants.
The likelihood of finding a fully matched unrelated donor for a patient who needs a bone marrow transplant varies greatly depending on a patient's ethnic background, and that ethnically diverse patients have – historically – been at a disadvantage. However, new research shows that when donor registry models are expanded to include mismatched unrelated donors, finding access for patients may greatly improve.[1]
Based on this understanding, Spellman believes that mismatched unrelated donors hold the key to erasing the gap in donor availability and deliver allogeneic hematopoietic cell transplantation (HCT) to all patient populations.
For more information about the Center for International Blood and Marrow Transplant Research, please visit the organization's website.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon or contact the sales team.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine.
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.
Reference
[1] Spellman S. Is finding a Donor for All in Need of Allogeneic HCT Possible? New Modeling Says Yes - Onco;Zine on September 5, 2022. [Link to article]
A Fantastic Voyage: From Magic Bullet to Antibody-drug Conjugates (US Version)
From Peter Hofland | Part of the The OncoZine Brief series | 44:34
In this –this episode of the Onco’Zine Brief, Peter Hofland talks with Dr. Matthias Bucerius, Vice President and General Manager at MilliporeSigma.
Dr. Bucerius is responsible for Contract Development and Manufacturing Organisation or CDMO-business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
In this program Hofland and Bucerius talk about antibody-drug conjugates or ADCs.
Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies.
What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs.
This combination makes these agents uniquely targetable therapies.
And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.
In this episode of the Onco'Zine Brief, Peter Hofland is talking with Dr. Matthias Bucerius, Vice President and General Manager at MilliporeSigma. Bucerius is responsible for Contract Development and Manufacturing Organisation or CDMO-business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates.
Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies. What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine.
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee the home of artisan roasted coffee